CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences

Aspire Biopharma Holdings, Inc.

Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.
Kraig Higginson, Chairman, appointed Interim CEO; company searching for permanent CEO.
Gary Stein resigns as independent Director and Audit Committee chair; Howard Doss succeeds him.
Barbara Sher resigns as director citing irreconcilable differences with company policies and direction.
No disagreements cited for Howe or Stein; Sher's resignation letter provided to company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.